Reprise Biomedical

Focus: Reprise Biomedical is a newly-founded (2024) medical device company specializing in biological wound matrices manufactured using proprietary perfusion decellularization technology. The company is focused on the diabetic foot ulcer market with acellular, porcine-derived products.

Wound Care

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Reprise Biomedical

AI assessmentNot Hiring

No open roles listed right now. Follow Reprise Biomedical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Acellular Porcine-Derived Wound Matrix

Diabetic Foot Ulcers (DFUs)

N/A

Clinical Trials (1)

NCT06939673Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care

N/A

Help build intelligence for Reprise Biomedical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly public (2024) medical device company with proprietary technology in a large, underserved wound care market
Focused pipeline targeting diabetic foot ulcers, a high-burden indication with significant clinical and commercial potential
Ownership stake potential and early-stage influence given company's nascent stage

Watch Out For

Extremely early-stage with no revenue, no approved products, and unproven commercial viability — typical startup risks apply
Minimal disclosed hiring (1 open sales role) and sparse public information suggest limited operational scale and resources
No published data, no disclosed funding details, and opaque financial position create uncertainty about runway and strategic direction

Generated by Claude from Reprise Biomedical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Miro3D Wound Matrix

Diabetic Foot Ulcers (DFUs)

N/A

Clinical Trials (1)

NCT06939686Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo